Skip to main content
. 2018 Jul 19;6(3):73. doi: 10.3390/microorganisms6030073

Figure 3.

Figure 3

PREVYMIS™ (letermovir) a recently (2017) FDA-approved drug for the prevention of Human cytomegalovirus (HCMV) infection and disease in organ transplant patients.